Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amuvatinib - Astex Pharmaceuticals

Next Previous
Drug Profile

Amuvatinib - Astex Pharmaceuticals

Alternative Names: Amuvatinib hydrochloride; HPK-56; MP-470; MP-470.HCL

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Montigen
  • Developer Astex Pharmaceuticals
  • Class Amides; Antineoplastics; Benzofurans; Dioxoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action DNA repair inhibitors; Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-met inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Glioblastoma; Small cell lung cancer

Most Recent Events

  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 21 Sep 2012 Efficacy data from the phase II ESCAPE trial in Small cell lung cancer released by Astex Pharmaceuticals
  • 21 Sep 2012 Amuvatinib is available for licensing as of 21 Sep 2012. http://www.astx.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top